



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SMARCA2/BRM Recombinant Monoclonal Antibody [BLR302M]

Rabbit Recombinant Monoclonal

Purified	RefSeq ID	NP_003061.3
Catalog No. A700-302CF	Uniprot ID	P51531
Lot No. 1	GeneID	6595

APPLICATIONS	IHC, ICC, Flow Cyt
SPECIES REACTIVITY	Human, Mouse
AMOUNT	100 µl
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) with 0.1% BSA and 0.09% Sodium Azide
ISOTYPE	IgG
CLONE #	BLR302M
ORIGIN	USA
PRODUCTION PROCEDURES	Recombinant antibody was purified from cell culture supernatant.

Immunogen was a peptide representing a region between residue 100 and 150 of human SMARCA2/BRM using the numbering given in entry NP_003061.3 (Gene ID 6595).

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

A700-302CF is the carrier-free formulation of 2971A-2B9. This product is optimized for conjugation with enzymes, fluorochromes, biotin, radioisotopes, oligonucleotides, microspheres, and other reagents. The optimal experimental concentration of the antibody post-conjugation must be determined by the investigator.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: February 28, 2024